JESSICA CUEVAS ROSAS: Open Payments
NPI 1942809009 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,944 in 127 payments from 20 companies in 2025. Trend: 2023 $6,039 · 2024 $4,894 · 2025 $2,944
Food & beverage: $2,944
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 13 | $416 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $401 |
| Otsuka America Pharmaceutical, Inc. | 14 | $330 |
| Vanda Pharmaceuticals Inc. | 13 | $277 |
| Lundbeck LLC | 12 | $270 |
| ABBVIE INC. | 15 | $241 |
| Neurocrine BioSciences, Inc. | 9 | $234 |
| Teva Pharmaceuticals USA, Inc. | 9 | $174 |
| E.R. Squibb & Sons, L.L.C. | 4 | $104 |
| Axsome Therapeutics, Inc. | 4 | $99 |
Products named: REXULTI, CAPLYTA, FANAPT, SPRAVATO, VRAYLAR, INGREZZA, INVEGA SUSTENNA, UZEDY.
Industry payments across CA — which companies pay providers there.
